These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24390981)

  • 21. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
    Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
    ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation.
    Diao Y; Wang X; Wan Y; Zhong J; Gao D; Liu Y; Gao N; Li W; Liu B; Huang X; Jin Z; Peng B; Wang Z; Fu L; Chen S; Jin G
    Oncol Rep; 2016 Feb; 35(2):793-800. PubMed ID: 26718332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.
    Chuang CM; Monie A; Hung CF; Wu TC
    J Biomed Sci; 2010 Apr; 17(1):32. PubMed ID: 20426849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
    Hayashi T; Chan M; Norton JT; Wu CC; Yao S; Cottam HB; Tawatao RI; Corr M; Carson DA; Daniels GA
    Melanoma Res; 2011 Feb; 21(1):66-75. PubMed ID: 21030882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma.
    Zhu J; He S; Du J; Wang Z; Li W; Chen X; Jiang W; Zheng D; Jin G
    J Hematol Oncol; 2015 Mar; 8():21. PubMed ID: 25887995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
    Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
    BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.
    Gao N; Zhong J; Wang X; Jin Z; Li W; Liu Y; Diao Y; Wang Z; Jiang W; Jin G
    Sci Rep; 2016 Dec; 6():39598. PubMed ID: 28000738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
    Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
    Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Cheadle EJ; Lipowska-Bhalla G; Dovedi SJ; Fagnano E; Klein C; Honeychurch J; Illidge TM
    Leukemia; 2017 Jul; 31(7):1611-1621. PubMed ID: 27890931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
    Ito H; Ando T; Arioka Y; Saito K; Seishima M
    Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of TLR3 and TLR7 activation in uterine NK cells from non-obese diabetic (NOD) mice.
    Lin Y; Ren L; Wang W; Di J; Zeng S; Saito S
    J Reprod Immunol; 2009 Oct; 82(1):12-23. PubMed ID: 19560213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with 8-OH-modified adenine (TLR7 ligand)-allergen conjugates decreases T helper type 2-oriented murine airway inflammation.
    Nencini F; Pratesi S; Petroni G; Filì L; Cardilicchia E; Casini A; Occhiato EG; Calosi L; Bani D; Romagnani S; Maggi E; Parronchi P; Vultaggio A
    Immunology; 2015 Aug; 145(4):570-82. PubMed ID: 25930741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4
    Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
    Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
    Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toll-like receptor 7 agonist imiquimod prevents the progression of SLE in MRL/lpr mice via inhibiting the differentiation of T follicular helper cells.
    Duan X; Shen C; Zhang X; Wu L; Chen J; Ma B; Wang Q; Sun P; Lan Y; Su C
    Int Immunopharmacol; 2020 Mar; 80():106239. PubMed ID: 32007709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
    Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
    Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
    Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
    J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
    Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.